National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) sits in the top decile of US sponsors by registered trial count (#74 of 15,742 sponsors by registered trial count).
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK): 490 sponsored US clinical trials, 50 recruiting.
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) sponsors 490 registered US clinical trials on ClinicalTrials.gov, 50 of them currently recruiting, and 398 completed. 69 of these trials are in Phase 3-4 (later-stage) and 178 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Obesity, with 25 trials.
Top-decile sponsor footprint
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) ranks in the top decile of sponsors by registered trial count (#74 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
398 of 424 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (93.9%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
490 total, page 2 of 10
Rituximab-pvvr and Abatacept vs Rituximab-pvvr Alone in New Onset Type 1 Diabetes
NCT03929601
Janus Kinase (JAK) Inhibitors to Preserve C-Peptide Production in New Onset Type 1 Diabetes (T1D)
NCT05743244
People With CHC Who Achieved a Sustained Virological Response Following Therapy With Direct Acting Antiviral Agents
NCT03520660
Compassionate Use of Metreleptin in Previously Treated People With Partial Lipodystrophy
NCT02262806
Compassionate Use of Metreleptin in Previously Treated People With Generalized Lipodystrophy
NCT02262832
Effect of Metreleptin Therapy in the Treatment of Severe Insulin Resistance
NCT00085982
Platform Trial in Stage 1 Diabetes: Comparing Golimumab vs Placebo
NCT07683026
Platform Trial to Delay Stage 3 Diabetes: Comparing Teplizumab With ATG
NCT07216391
177Lu-DOTA-EB-TATE in Adult Patients With Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid Cancer
NCT06991738
Evaluation of the Clinical Spectrum of Diabetes and Obesity in Youth and Adults
NCT07388537
Prevalence and Development of Liver Dysfunction in Hematopoietic Stem Cell Transplant
NCT05722210
Effects of Meal Macronutrients on Postprandial Lipids
NCT07313787
Trial of the Combination of Alpha-Lipoic Acid and Mirabegron in Women and in Men With Obesity
NCT05713799
Assessing the Impact of Perceptions of Unpredictability on Objective Measures of Food Consumption and Metabolism
NCT06690294
Discovering Determinants of Food Intake by Application of Artificial Intelligence to Complex, High-Dimensional Data
NCT07637656
Longitudinal Immunophenotyping of Patients With Inflammatory Bowel Disease
NCT07619547
STOP-T1D Low-Dose (ATG)
NCT04291703
Study to Determine the Response to COVID-19 Vaccination and Prevalence of COVID-19 in Subjects With Chronic Liver Disease
NCT05669677
Effect of Ultra-processed Versus Unprocessed Diets on Energy Metabolism
NCT05290064
The Impact of the COVID-19 Pandemic on Eating Behavior and Weight Change
NCT04896060
Vitamin E Dosing Study
NCT04801849
HOPE Consortium Trial to Reduce Pain and Opioid Use in Hemodialysis
NCT04571619
A Multiple Ascending Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC0361-0041
NCT04279613
Prebiotics and Metformin Improve Gut and Hormones in Type 2 Diabetes in Youth (MIGHTY-fiber)
NCT04209075
Famine From Feast: Linking Vitamin C, Red Blood Cell Fragility, and Diabetes
NCT02107976
Effects of Low Fat Versus Low Carbohydrate Diets on Energy Metabolism
NCT03878108
Losartan for the Treatment of Pediatric NAFLD
NCT03467217
Brain Dopamine Function in Human Obesity
NCT03648892
Hydroxychloroquine in Individuals At-risk for Type 1 Diabetes Mellitus
NCT03428945
Treatment of Chronic Delta Hepatitis With Lonafarnib, Ritonavir and Lambda Interferon
NCT03600714
Effect of Ultra Processed Versus Unprocessed Diets on Energy Intake
NCT03407053
Effect of Isocaloric Ultra Processed Versus Unprocessed Diets on Insulin Sensitivity
NCT03189121
Hepatitis B Reactivation During Treatment With Direct-Acting Antiviral Agents for Chronic Hepatitis C Infection
NCT03248622
Title: Therapeutic Targets in African-American Youth With Type 2 Diabetes
NCT02960659
Food Intake Response to Short-Term Modifications of Metabolism in Humans
NCT02939404
Longitudinal Assessment of Transient Elastography in Cystic Fibrosis
NCT03001388
MRI to Characterize and Predict CF Liver Disease in PUSH Cohort
NCT02979340
Optimizing HBV Care Cascade Among Foreign-Born in the United States (FOCUS-HBV Study)
NCT05621304
A Phase 1 Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ManNAc in Subjects With Primary Podocyte Diseases
NCT02639260
Immune Effects of Oral Insulin in Relatives at Risk for Type 1 Diabetes Mellitus (TN20)
NCT02580877
Efficacy, Safety and Tolerability of ISIS 304801 in People With Partial Lipodystrophy With an Open-Label Extension
NCT02639286
Dynamic Post-Prandial Metabolism in Patients With Non-Alcoholic Fatty Liver Disease
NCT02520609
Quantifying the Persistence of Metabolic Adaptation and Weight Regain Following Extreme Weight Loss
NCT02544009
Treatment of Chronic Delta Hepatitis With Lonafarnib and Ritonavir
NCT02511431
Viral Kinetics, Interferon Stimulated Genes (ISGs) and mirRNA Among Subjects Infected With Different Hepatitis C Virus Genotypes During Therapy With Sofosbuvir and GS-5816
NCT02468648
Deciphering the Mechanisms Involved in Microbial Translocation Across the Spectrum of HCV Associated Liver Fibrosis
NCT02400216
Thyroid Hormone to Induce Non-Insulin Mediated Glucose Disposal in People With Insulin Receptor Mutations
NCT02457897
Palmitate Breath Test to Assess Fatty Acid Oxidation in Non Alcoholic Fatty Liver Disease (NAFLD)
NCT02363309
Add-on Peginterferon Following Nucleos(t)Ide Analogue Treatment
NCT02364336
Cross Calibration of Two Dual Energy Densitometers and Comparison of Regional Adipose Tissue Measurements by iDXA and MRI
NCT02346474
What is open in the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) pipeline
50 recruiting of 490 indexed (10% open); 398 completed (81%).
Phase mix: 69 late (III/IV) vs 178 early (I/II) (early-phase heavy).
Top condition: Obesity (25 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK): open-pipeline peers nationwide
Peers matched on 490 registered trials and 10% open enrollment, not the therapeutic-area sidebar.
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 490 trials (± recruiting share)
- Beth Israel Deaconess Medical Center · 488 trials · 14% recruiting
- Fred Hutchinson Cancer Center · 483 trials · 12% recruiting
- National Heart, Lung, and Blood Institute (NHLBI) · 501 trials · 12% recruiting
- H. Lee Moffitt Cancer Center and Research Institute · 502 trials · 16% recruiting
Sponsors near 10% open enrollment (± trial volume)
- Mirati Therapeutics · 10% recruiting · 49 trials
- James J. Peters Veterans Affairs Medical Center · 10% recruiting · 39 trials
- California Pacific Medical Center Research Institute · 10% recruiting · 29 trials
- National Institute of Environmental Health Sciences (NIEHS) · 10% recruiting · 145 trials
Related
What to do with this National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) page
490 registered trials is a research-attention snapshot, not an endorsement of National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) or any single study.
- 50 of National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)'s trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Obesity is the condition National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Obesity trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) pipeline card: 490 registered trials from official public datasets.Report a data error.